Market News AIOpen the app

Jefferies has cut its price target for Moderna to $215, down from $230.

OpinionRead the original at marketscreener.com
Bad for MRNA

Jefferies lowered its target for Moderna shares from $230 to $215. That signals a less favorable view, though the report gives no new facts about Moderna's business.

MRNA · Moderna, Inc.

AI read · Bad for MRNA

The AI's read

A lower target means Jefferies now expects less from Moderna shares than before. The story gives no new sales, product, or cash information, so this is one firm's changed view, not evidence that Moderna's business has worsened.

Get alerts for MRNA

Follow Moderna, Inc. (MRNA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MRNA
Free on the App Store and Google Play, or on the web.